Amicus Therapeutics (NASDAQ:FOLD) Coverage Initiated by Analysts at Stifel Nicolaus

Last updated on Monday, March 8, 2021 | 2021 MarketBeat

Analysts at Stifel Nicolaus started coverage on shares of Amicus Therapeutics (NASDAQ:FOLD) in a report released on Monday, Benzinga reports. The brokerage set a "hold" rating and a $13.00 price target on the biopharmaceutical company's stock. Stifel Nicolaus' price target suggests a potential upside of 24.05% from the company's current price.

Several other equities analysts also recently issued reports on FOLD. Robert W. Baird reaffirmed a "buy" rating on shares of Amicus Therapeutics in a research note on Wednesday, March 3rd. Citigroup dropped their price target on shares of Amicus Therapeutics from $27.00 to $16.00 in a research note on Friday, February 12th. Cantor Fitzgerald cut shares of Amicus Therapeutics from an "overweight" rating to a "neutral" rating and decreased their price objective for the stock from $30.00 to $17.00 in a research report on Friday, February 12th. JPMorgan Chase & Co. cut shares of Amicus Therapeutics from an "overweight" rating to a "neutral" rating and set a $19.00 price objective for the company. in a research report on Friday, February 12th. Finally, Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell cut shares of Amicus Therapeutics from a "buy" rating to a "neutral" rating and increased their price objective for the stock from $20.00 to $27.00 in a research report on Thursday, December 10th. One analyst has rated the stock with a sell rating, eight have given a hold rating and five have given a buy rating to the company's stock. The stock presently has a consensus rating of "Hold" and an average price target of $19.89.

Shares of NASDAQ:FOLD opened at $10.48 on Monday. The firm has a 50 day simple moving average of $16.82 and a 200 day simple moving average of $18.31. The company has a market cap of $2.77 billion, a price-to-earnings ratio of -9.11 and a beta of 1.57. Amicus Therapeutics has a one year low of $6.25 and a one year high of $25.39. The company has a debt-to-equity ratio of 1.21, a current ratio of 5.24 and a quick ratio of 5.10.

Amicus Therapeutics (NASDAQ:FOLD) last released its quarterly earnings results on Sunday, February 28th. The biopharmaceutical company reported ($0.27) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.23) by ($0.04). Amicus Therapeutics had a negative net margin of 120.18% and a negative return on equity of 73.81%. As a group, analysts expect that Amicus Therapeutics will post -1.03 EPS for the current year.

In other Amicus Therapeutics news, insider Hung Do sold 111,125 shares of the firm's stock in a transaction on Monday, December 14th. The shares were sold at an average price of $23.88, for a total value of $2,653,665.00. Following the transaction, the insider now directly owns 409,682 shares of the company's stock, valued at $9,783,206.16. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO John F. Crowley sold 50,000 shares of the firm's stock in a transaction on Wednesday, January 20th. The shares were sold at an average price of $21.51, for a total transaction of $1,075,500.00. Following the completion of the transaction, the chief executive officer now directly owns 940,996 shares in the company, valued at $20,240,823.96. The disclosure for this sale can be found here. Insiders sold 228,139 shares of company stock worth $5,264,285 over the last ninety days. Insiders own 2.50% of the company's stock.

Several institutional investors and hedge funds have recently added to or reduced their stakes in FOLD. Lone Pine Capital LLC bought a new position in shares of Amicus Therapeutics during the fourth quarter valued at about $154,213,000. Morgan Stanley lifted its position in shares of Amicus Therapeutics by 33.2% during the third quarter. Morgan Stanley now owns 11,113,785 shares of the biopharmaceutical company's stock valued at $156,926,000 after purchasing an additional 2,768,405 shares in the last quarter. Norges Bank bought a new position in shares of Amicus Therapeutics during the fourth quarter valued at about $63,431,000. Canada Pension Plan Investment Board lifted its position in shares of Amicus Therapeutics by 2,528.2% during the fourth quarter. Canada Pension Plan Investment Board now owns 1,350,610 shares of the biopharmaceutical company's stock valued at $31,186,000 after purchasing an additional 1,299,220 shares in the last quarter. Finally, UBS Asset Management Americas Inc. lifted its position in shares of Amicus Therapeutics by 418.2% during the third quarter. UBS Asset Management Americas Inc. now owns 1,505,578 shares of the biopharmaceutical company's stock valued at $21,259,000 after purchasing an additional 1,215,044 shares in the last quarter.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, engages in the discovery, development, and commercialization of therapies to treat a range of rare and orphan diseases. The company offers Galafold, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting Phase 3 (ATB200-03) clinical study of AT-GAA for Pompe disease.

Featured Story: Straddles

Analyst Recommendations for Amicus Therapeutics (NASDAQ:FOLD)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]



7 Things You Need To Know About Cryptocurrency

The Cryptocurrency Market Is About To Boil Over

The cryptocurrency was quiet for years, but it’s starting to boil over once again. With the price of Bitcoin up 550%, it certainly seems like the sky is the limit.

Whether or not you choose to trade Bitcoin or any other cryptocurrency, it is important to understand what it is and the trends driving it.

The bottom line, however, is that the world’s money is flowing onto the blockchain, and the use of cryptocurrency is growing at an exponential rate.

View the "7 Things You Need To Know About Cryptocurrency".


MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.